Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-18T06:52:31.270Z Has data issue: false hasContentIssue false
  • English
  • Français

The Cost-Effectiveness of Octreotide Acetate in the Treatment of Carcinoid Syndrome and Vipoma

Published online by Cambridge University Press:  10 March 2009

Warren H. Schonfeld ,
Eric P. Elkin ,
Eugene A. Woltering ,
Irvin M. Modlin ,
Lowell Anthony ,
Kathleen F. Villa  and
Martin Zagari
Warren H. Schonfeld
Affiliation:
Lewin-TAG, Inc.
Eric P. Elkin
Affiliation:
Public Health Institute
Eugene A. Woltering
Affiliation:
Louisiana State University Medical Center
Irvin M. Modlin
Affiliation:
Yale University School of Medicine
Lowell Anthony
Affiliation:
Louisiana State University Medical Center
Kathleen F. Villa
Affiliation:
Lewin-TAG, Inc.
Martin Zagari
Affiliation:
Johnson & Johnson
Get access Rights & Permissions [Opens in a new window]

Abstract

Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma. For each condition, using octreotide was associated with doubled survival time. Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 14 , Issue 3 , Summer 1998 , pp. 514 - 525
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Diaco, D. S., Hajarizadeh, H., Mueller, C. R., et al. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. American Journal of Surgery, 1995,169, 523–28.CrossRefGoogle ScholarPubMed
2.Eddy, D. M.Screening for cervical cancer. Annals of Internal Medicine, 1990, 113, 214–26.CrossRefGoogle ScholarPubMed
3.Eddy, D. M.Screening for breast cancer. Annals of Internal Medicine, 1989, 111, 389–99.CrossRefGoogle ScholarPubMed
4.Gorden, P., Comi, R. J., Maton, P. N., et al. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Annals of Internal Medicine, 1989, 110, 35–50.CrossRefGoogle ScholarPubMed
5.Gorsky, R. D., & Colby, J. P. J.The cost-effectiveness of prenatal care in reducing low birth weight in New Hampshire. Health Services Research, 1989, 24, 583–98.Google ScholarPubMed
6.Hollenberg, J.SMLTREE version 2.99 decision analysis software. Roslyn, NY: 1993.Google Scholar
7.Kaplan, L. M.Endocrine tumors of the gastrointestinal tract and pancreas. In Wilson, J. D., Braunwald, E., Isselbacher, K. J., et al. (eds.), Harrison's principles of internal medicine, 12th ed.New York: McGraw-Hill, Inc., 1991.Google Scholar
8.Kvols, L. K.The carcinoid syndrome: A treatable malignant disease. Oncology, 1988, 2, 33–41.Google ScholarPubMed
9.Kvols, L. K., Moertel, C. G., O'Connell, M. J., et al. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine, 1986, 315, 663–66.CrossRefGoogle ScholarPubMed
10.Kvols, L. K., & Reubi, J. C.Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncologica, 1993, 32, 197–201.CrossRefGoogle ScholarPubMed
11.Littenberg, B., Garber, A. M., & Sox, H. C.Screening for hypertension. Annals of Internal Medicine, 1990, 112, 192–202.CrossRefGoogle ScholarPubMed
12.Modlin, I. M., & Sandor, A.An analysis of 8305 cases of carcinoid tumors. Cancer, 1997, 79, 813–29.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
13.Physician's Fee and Coding Guide. Augusta, GA: HealthCare Consultants of America, Inc., 1994.Google Scholar
14.Redbook. Montvale, NJ: Medical Economics Company, Inc., 1994.Google Scholar
15.Russell, L. B.Some of the tough decisions required by a national health plan. Science, 1989, 246, 892–96.CrossRefGoogle ScholarPubMed
16.Sonnenberg, F. A., & Beck, J. R.Markov models in medical decision making: A practical guide. Medical Decision Making, 1993, 13, 322–38.CrossRefGoogle ScholarPubMed
17.Trautmann, M. E., Neuhaus, C., Lenze, H., et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Hormone and Metabolic Research, 1993, 27(suppl.), 24–27.Google ScholarPubMed
18.Vinik, A. I., & Moattari, A. R.Neuroendocrine tumors, secretory diarrhea, and responses to somatostatin. In Lebenthal, E. & Duffey, M. (eds), Textbook of secretory diarrhea. New York: Raven Press, Ltd., 1990.Google Scholar
19.Wood, A. J. J, Lamberts, S. W. J, van Der Lely, A.-J., et al. Drug therapy. New England Journal of Medicine, 1996, 334, 246–54.Google Scholar